RM-MET / Metabolic and incretin signalling
Mazdutide
Also known as: IBI362 · IBI-362 · LY3305677
Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.
What this is
Mazdutide is a modified dual-receptor agonist developed under the identifiers IBI362 and LY3305677. The library keeps those aliases together so study records are not split across different names.
Evidence position
Randomized phase 3 data supports Grade B. The evidence belongs to the defined investigational molecule and trial formulation.
What the record does not establish
Published outcomes do not authenticate a separately manufactured powder, confirm a label, or transfer a finished-product safety record to another material.
Sources
- 01Mazdutide compound recordPubChem
- Shows
- Registry identity, structure, formula, CAS number and development synonyms
- Does not show
- A registry record does not establish clinical status or lot quality
- 02Mazdutide versus placebo in adults with type 2 diabetesPubMed
- Shows
- Randomized phase 3 human monotherapy results
- Does not show
- Sponsor-involved trial in a defined population; not evidence about any research vial
- 03DREAM-PRE mazdutide studyClinicalTrials.gov
- Shows
- Current registry record, intervention aliases, design and status
- Does not show
- Registration does not establish positive results, approval or material quality
External database index
LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE
Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.
PUBCHEM / IDENTITY
Mazdutide
- CID
- 167312357
- Formula
- C207H317N45O65
- Mass
- 4476
PUBMED / FOUND RECORDS
- Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.The New England journal of medicine / 2025 Jun 12PMID 40421736 / DOI 10.1056/NEJMoa2411528
- Emerging pharmacotherapies for obesity: A systematic review.Pharmacological reviews / 2025 JanPMID 39952695 / DOI 10.1124/pharmrev.123.001045
- Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial.EClinicalMedicine / 2022 DecPMID 36247927 / DOI 10.1016/j.eclinm.2022.101691
- Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.Metabolism: clinical and experimental / 2024 DecPMID 39305981 / DOI 10.1016/j.metabol.2024.156038
- A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity.Nature communications / 2023 Dec 14PMID 38092790 / DOI 10.1038/s41467-023-44067-4
CLINICALTRIALS.GOV / FOUND RECORDS
- Clinical Study of IBI362 in Healthy Chinese Male SubjectsCOMPLETED / PHASE1 / Innovent Biologics (Suzhou) Co. Ltd.NCT04773977 / DIRECT intervention MATCH: IBI362
- A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) InhibitorNOT_YET_RECRUITING / PHASE3 / Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.NCT07417306 / DIRECT intervention MATCH: Mazdutide
- A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or OverweightCOMPLETED / PHASE2 / Eli Lilly and CompanyNCT06124807 / DIRECT intervention MATCH: Mazdutide
- A Study of LY3305677 in Healthy ParticipantsCOMPLETED / PHASE1 / Eli Lilly and CompanyNCT02972645 / DIRECT intervention MATCH: LY3305677
- A Study of LY3305677 in Participants With Obesity Or OverweightCOMPLETED / PHASE1 / Eli Lilly and CompanyNCT05623839 / DIRECT intervention MATCH: LY3305677